News
XENiOS® invests $2.6 million in XOR-Labs TorontoPartnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017 ...
Heilbronn, Germany's Xenios has invested $2.6 million in lung transplantation specialist Xor-Labs Toronto. Xor's Ex Vivo organ repair technology improves the quality of transplanted lungs. The ...
Press Release XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto ("XOR"), a spin-off of Toronto General Hospital at University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback